Invesco’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,693
| Closed | -$205K | – | 3743 |
|
|
2025
Q4 | $205K | Sell |
15,693
-380
| -2% | -$4.54K | ﹤0.01% | 3521 |
|
|
2025
Q3 | $117K | Buy |
16,073
+911
| +6% | +$6.17K | ﹤0.01% | 3663 |
|
|
2025
Q2 | $81.3K | Sell |
15,162
-2,389
| -14% | -$11.6K | ﹤0.01% | 3674 |
|
|
2025
Q1 | $93.7K | Sell |
17,551
-441
| -2% | -$3.08K | ﹤0.01% | 3632 |
|
|
2024
Q4 | $161K | Sell |
17,992
-296,814
| -94% | -$3.15M | ﹤0.01% | 3550 |
|
|
2024
Q3 | $3.47M | Buy |
314,806
+300,701
| +2,132% | +$3.34M | ﹤0.01% | 2409 |
|
|
2024
Q2 | $128K | Sell |
14,105
-281,345
| -95% | -$2.75M | ﹤0.01% | 3719 |
|
|
2024
Q1 | $4.16M | Buy |
295,450
+283,962
| +2,472% | +$3.54M | ﹤0.01% | 2344 |
|
|
2023
Q4 | $88.2K | Sell |
11,488
-12,417
| -52% | -$68.7K | ﹤0.01% | 3700 |
|
|
2023
Q3 | $178K | Buy |
23,905
+11,249
| +89% | +$95.9K | ﹤0.01% | 3632 |
|
|
2023
Q2 | $105K | Buy |
+12,656
| New | +$146K | ﹤0.01% | 3716 |
|
|
2021
Q2 | – | Sell |
-5,059
| Closed | -$88K | – | 3965 |
|
|
2021
Q1 | $88K | Buy |
5,059
+106
| +2% | +$1.92K | ﹤0.01% | 3773 |
|
|
2020
Q4 | $64K | Buy |
+4,953
| New | +$88.3K | ﹤0.01% | 3710 |
|
|
2018
Q4 | – | Sell |
-276
| Closed | -$13K | – | 3817 |
|
|
2018
Q3 | $13K | Buy |
+276
| New | +$12.4K | ﹤0.01% | 3858 |
|
Invesco's ATXS Position: Q1 2026 in Review
Invesco sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 15,693 shares — an estimated $205K sold.
Invesco first reported a position in ATXS in Q3 2018 and held it in 14 quarters. The position peaked at $4.16M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Invesco reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Invesco sold 15,693 Astria Therapeutics shares in Q1 2026, an estimated $205K.
- Invesco first reported a position in Astria Therapeutics in Q3 2018 and held it in 14 quarters.
- Invesco's Astria Therapeutics position peaked at $4.16M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.